About this Research Topic
Epigenetic modifications and regulators have been demonstrated to be significantly changed in almost all human complex disease including cancers, autoimmune diseases, and psychological disorders. Since the discovery of epigenetic abnormalities in the early stage of disease, they are becoming the most promising biomarkers for diagnosis and prognosis. Meanwhile, epigenetic changes are inheritable and reversible; therefore, it shows great potential as pharmacotherapy targets as well as real-time surveillance of disease progression. Recently, different epigenetic sequencing and detection techniques have been developed to analyze DNA and RNA methylation (m5C, 5hmC, m6A), histone modification (H4K16ac, H3K9me3, H3K27me3 etc.), ncRNA (miRNA, circRNA, lncRNA, ceRNA etc.) which provided a great opportunity for biomarker identification.
Thanks to this scientific and technical progress, recent clinical diagnosis started to use epigenetic abnormalities such as non-invasive cell-free DNA methylation biomarker, SHOX2, SPET9 methylation biomarker for high-risk individual screening. Meanwhile, histone deacetylase inhibitors (HDAC inhibitors) have been widely used in various diseases, such as cancers, parasitic and inflammatory diseases, suggesting the potential of epigenetic modification in disease treatment. Recently, epigenetic profiles have been also applied to identify disease subtype for a better understanding of the disease pathology, therefore, these biomarkers would play more roles in personalized and precision medicine.
With this Research Topic, investigators can contribute Original Research articles, Review articles that will stimulate the continuing efforts to use epigenetic biomarker in personalized and precision medicine, including:
1) Epigenetic biomarker identification and evaluation;
2) Novel detection and sequencing techniques on epigenetic assay;
3) Novel statistic approach and tools on epigenetic and genetic analysis;
4) Interaction identification between genetics and epigenetics in precision medicine;
5) Approach and strategy of personalized precision medicine based on the integration of genetic and epigenetics.
Thanks to this scientific and technical progress, recent clinical diagnosis started to use epigenetic abnormalities such as non-invasive cell-free DNA methylation biomarker, SHOX2, SPET9 methylation biomarker for high-risk individual screening. Meanwhile, histone deacetylase inhibitors (HDAC inhibitors) have been widely used in various diseases, such as cancers, parasitic and inflammatory diseases, suggesting the potential of epigenetic modification in disease treatment. Recently, epigenetic profiles have been also applied to identify disease subtype for a better understanding of the disease pathology, therefore, these biomarkers would play more roles in personalized and precision medicine.
With this Research Topic, investigators can contribute Original Research articles, Review articles that will stimulate the continuing efforts to use epigenetic biomarker in personalized and precision medicine, including:
1) Epigenetic biomarker identification and evaluation;
2) Novel detection and sequencing techniques on epigenetic assay;
3) Novel statistic approach and tools on epigenetic and genetic analysis;
4) Interaction identification between genetics and epigenetics in precision medicine;
5) Approach and strategy of personalized precision medicine based on the integration of genetic and epigenetics.
Keywords: DNA methylation, Epigenetic, Biomarker, Personalized and Precision Medicine
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
